Your session is about to expire
← Back to Search
ZetaFuse™ Bone Graft for Spinal Repair in Breast Cancer (ZGMBC Trial)
ZGMBC Trial Summary
This trial is for patients with cancer that has spread to up to 5 areas, who have a spinal instability score of 3-9, who are having the ZetaFuse bone graft implanted in their spine to help with the tumor.
ZGMBC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowZGMBC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ZGMBC Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any vacant positions in this clinical investigation?
"Clinicaltrials.gov states this trial is actively seeking enrollees, which was first published on September 1st 2022 and the record most recently updated at a similar date."
How many individuals are engaged in this clinical experiment?
"Affirmative, clinicaltrials.gov presents evidence that this medical trial is presently in search of participants since its initial publishing on September 1st 2022. Ten individuals are needed across one site and the data was most recently updated on the same day it went live."
Is this investigation enrolling individuals who are fifty years or older?
"This trial's inclusion criteria mandates that applicants must be of an age between 22 and 75 years old."
Is it possible for me to participate in this clinical examination?
"This medical trial is seeking 10 female patients aged between 22 and 75 that have been diagnosed with primary breast cancer. To qualify, the patient must display a minimum SINS score of 3 and a maximum of 9, while also having no more than 5 metastases located at or below three sites. Additionally, they must possess normal spinal alignment and life expectancy in excess of 12 months. Finally, all participants need to provide signed consent forms as well as agree to comply with follow-up visits throughout the study duration."
Share this study with friends
Copy Link
Messenger